Clinical characteristics of patients with MA-ILD who responded to or failed conventional treatment (n = 54). Values are n unless otherwise specified.
| Clinical Characteristics | Responders, n = 31 | Nonresponders, n = 23 | p |
|---|---|---|---|
| Age at onset of myositis, yrs | 46.8 | 42.2 | 0.34 |
| Sex | |||
| Male | 6 | 10 | 0.055 |
| Female | 25 | 13 | |
| Race | |||
| Black | 14 | 12 | 0.12 |
| White | 13 | 9 | |
| Asian | 4 | 0 | |
| Hispanic | 0 | 2 | |
| Smoking history | |||
| Never | 20 | 18 | 0.068 |
| Former | 10 | 2 | |
| Active | 1 | 3 | |
| Myositis | |||
| Polymyositis | 20 | 10 | 0.013 |
| Dermatomyositis | 7 | 13 | |
| CADM | 4 | 0 | |
| Baseline CK, U/l | 2588.9 | 3431.0 | 0.20 |
| Baseline aldolase | 29.6 | 34.4 | 0.29 |
| Serologic data | |||
| ANA | 16 | 16 | 0.18 |
| Anti-Jo1 | 18 | 9 | 0.17 |
| SSA | 13 | 9 | 0.84 |
| Mi-2 | 1 | 2 | 0.39 |
| PL-7 | 0 | 1 | 0.43 |
| SRP | 1 | 1 | 0.68 |
| Ku | 0 | 1 | 0.43 |
| PFT, % | |||
| FVC | 62.5 | 60.4 | 0.39 |
| TLC | 68.8 | 68.3 | 0.46 |
| DLCO | 58.3 | 57.3 | 0.62 |
| CT chest | |||
| Honeycombing absent | 21 | 17 | 0.62 |
| Honeycombing present | 10 | 6 | |
| Lung histopathology | |||
| COP | 3 | 2 | 0.60 |
| UIP | 1 | 2 | |
| NSIP | 0 | 3 | |
| Others* | 1 | 2 | |
| Conventional DMARD | |||
| AZA | 19 | 16 | 0.53 |
| MTX | 8 | 9 | 0.30 |
| MMF | 6 | 5 | 0.55 |
↵* COP with NSIP, COP with hypersensitivity pneumonitis, and COP with diffuse alveolar damage. MA-ILD: myositis-associated interstitial lung disease; CADM: clinically amyopathic dermatomyositis; CK: creatine kinase; ANA: antinuclear antibody; SRP: signal recognition particle; PFT: pulmonary function test; FVC: forced vital capacity; TLC: total lung capacity; CT: computed tomography; COP: cryptogenic organizing pneumonia; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; DMARD: disease-modifying antirheumatic drugs; AZA: azathioprine; MTX: methotrexate; MMF: mycophenolate mofetil.